LumiThera Acquires Assets of Diagnostic Tool Developer MacuLogix.

MANews-(C)2009-2022

A wholly owned subsidiary of Washington, US-based medical device company LumiThera Inc. has acquired assets of Pennsylvania, US-based MacuLogix, Inc., offering early diagnosis of dry age-related macular degeneration, the company said.

Terms of the transaction were not disclosed.

MacuLogix, Inc. is the developer of the wearable AdaptDX Pro dark adaptometer.

LumiThera's announcement follows the release of its positive 13-month US Lightsite III treatment data in intermediate dry Age-related Macular Degeneration patients with the Valeda Light Delivery System.

The pivotal US study and previous clinical studies will support FDA submission for potential US approval.

Valeda is currently approved in Europe and several countries in Latin America.

LumiThera is a commercial-stage medical device company focussed on treating people affected by ocular damage and disease including dry age-related macular...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT